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The prevalence and cost of type-2-diabetes mellitus (T2DM) are escalating globally. The comorbidities between T2DM, depression and 
anxiety are common. Achieving high adherence to therapy, supported by lifestyle adjustment is the gold standard for good diabetes 
management. This study aimed to explore the impact of mental ill-health on medication adherence behaviors in patients diagnosed with 
T2DM. Participants were recruited from a single general medical practice in Birmingham, and randomly allocated into group A and group 
B. All participants had their HbA1c and blood pressure (BP) measured, their medication adherence, depression, and anxiety screened at each 
consultation. Of 64 patients, those with secondary school education, physically active, unemployed, did not have online access to resources, 
were mentally healthy and from Pakistani ethnicity, had better diabetes medications adherence. Regression analysis showed a significant 
statistical difference (p<0.05) in the unintentional diabetes medication adherence and anxiety scores favoring group A. BP showed a 
significant difference between baseline and endpoint but no difference was observed between groups. The use of Morisky® software has 
allowed the screening of the underlying cause of medication adherence, depression, and anxiety promptly. The study identified the importance 
of medication adherence in diabetes and the impact this has on HbA1c and mental health. The study also proposed two algorithms, one for 
T2DM patients in general and one for patients from the Muslim faith, and showed how clinicians can adapt their consultations to meet the 
needs of an individual.  
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The association between chronic long-term conditions such 
as type 2 diabetes mellitus (T2DM) and mental ill-health 
(MIH) is well known and well defined in the Diagnostic and 
Statistical Manual of Mental Disorders [1-3]. Many authors 
have investigated the correlation between the two conditions, 
to establish if one can lead to the other. A recent study 
measuring the relationship between depression and 
prevalence of T2DM in a community setting showed that 
most medications used for the treatment of depression can 
lead to weight gain, and consequentially increase the patient's 
risk to develop or worsen T2DM [4]. The authors also 
concluded that for the patient diagnosed with depression, the 
risk for T2DM increased by 20% and further increased after 
the initiation of medications. Another study showed that the 
risk of depression increased in T2DM patients diagnosed with 
diabetic neuropathy [5-7] concluded that the possible 
pathway is indirect, due to obesity as a result of loss of 
motivation for physical activity, emotional eating, and the 
side effects of the used medication. 
Kumar found that the presence of T2DM is related to 
structural changes in the brain and linked insulin resistance to 
a depressed mood [8, 9]. Pouwer et al. [10] identified the link 
between stress, depression, and anxiety, and increasing the 
risk of T2DM. The increased risk was reported to be a result 
of changes in behavior leading to poor lifestyle choices such 
as altered eating patterns, poor food choices, consumption of 
a large amount of food, or more frequent meals. This is 
further compounded by physical inactivity, and self-
medicating with high alcohol consumption. Another pathway 
they described was that behavior changes due to mental 
disorders can cause a long-term activation of the 
hypothalamic-pituitary-adrenal axis, leading to a sympathetic 
nervous system effect on appetite causing a knock-on effect 
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Aim  
This study aimed to explore the impact of mental ill-health, 
on medication adherence behaviors in patients diagnosed 
with T2DM.  
MATERIALS AND METHODS 
This was a cohort observational study where the study 
population was randomly divided into cohort A (received 
three consultations, three months apart) and group B 
(received two consultations, 6 months apart). Ethics approval 
was received from the Health Research Authority (HRA) 
through the Integrated Research Application System (IRAS). 
The population (n=64) was recruited out of all patients (n=71) 
on the register of one general medical practice in 
Birmingham, UK. The study process is set out in Figure 1. 
Patients were recruited through invitation letters posted to 
their homes by the clinic’s administration staff. The invitation 
letter included the participant information sheet and the 
selection criteria. Those who responded to the invitation were 
contacted by the surgery to be booked in for a consultation 
with the researcher. At the beginning of the consultation, the 
researcher explained the study procedures and duration, then, 
the researcher confirmed the patient’s eligibility to 
participate. Those admitted were then asked to sign the 
consent form if they were still interested to participate. They 
were then moved to the waiting room, where they were given 
the demographics questionnaire for self-completion. This was 
collected at the beginning of the baseline consultation. 
Further demographics and previous HbA1c records were 
collated from a patient electronic medical record (EMR). 
Patient adherence to therapy was screened using the 
Morisky® 8-items electronic tool (MMAS-8©) twice; once 
for all their medications and again for diabetes medications 
only [11]. The Clinically Useful Depression Outcome Scale 
(CUDOS©) was used to screen for depression and the 
Clinically Useful Anxiety Outcome Scale (CUXOS©) was 
used to screen for anxiety [12-15]. Patients were asked to 
score their well-being on a scale from 1-5 where 1 least sense 
of well-being and 5 is the maximum sense of wellbeing. A 
medicine use review was then conducted and a care plan was 
developed, including any required education sessions or 
referrals. Patients were then randomly segregated into group 
A and group B using a randomization table generated in 
Microsoft® Excel™. All the data collected throughout the 
study were then analyzed for trends between the two groups 
and by demographics. 
 
 
Figure 1. Diagrammatic Illustration of the Study Plan 
Patient’s records were reviewed to take note of the dates of, 
and reasons for, the most recent visits (during the past 12 
months) to their endocrinologist, optometrist, or podiatrist, 
most recent HbA1c results, and most recent BP measurement. 
When HbA1c and BP recent records, (within the past 4 
weeks), were not found, an HbA1c test was ordered and BP 
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was measured. The sample was calculated based on an 
improvement by one score point in patients' medication 
adherence as 6 patients in each group. This was multiplied by 
5 as the minimum (n=30 patients per group) and by 10 as the 
maximum (60 patients per group) to accommodate 
withdrawals. Recruitment continued for 6 months which 
enabled the intervention to be concluded within 12 months. 
Patients were eligible if they were diagnosed with T2DM, 
able to self-consent, and 18 years of age or over. To prevent 
unnecessary stress on patients, those who were diagnosed 
with conditions such as severe dementia or severe mental 
illness or undertaking acute treatment for cancer were not 
invited.  
RESULTS AND DISCUSSION  
Out of 71 patients who were eligible to participate, 64 (90%) 
signed the informed consent to voluntarily enroll in the study. 
The consultations at the initial enrolment were termed 
‘baseline (BL)’, the 3-months consultations were termed 
‘midterm (MT)’ and the 6-months consultation was termed 
‘endpoint (EP)’.  
Table 1 provides the descriptive summary of the study 
population by all measurable output variables. 
 
Table 1. Overall mean values, SD (+/-) with minimum and maximum values at baseline and endpoint. 
Variables 
BL EP 
 Range  Range 
Mean SD+/- Min Max Mean SD+/- Min Max 
HbA1c 8 1.7 6.4 13 7.7 1.7 5.8 12.7 
MMAS-8© Diabetes medications intentional 3.4 1.1 0 4 3.3 0.7 2 4 
MMAS-8© Diabetes medications unintentional 3.5 0.7 0.8 4 3.7 0.5 1.8 4 
CUDOS© 1 0.2 1 2 1 0 1 1 
CUXOS© 1 0.2 1 2 1 0 1 1 
MMAS-8© Chronic diseases medications intentional 3.6 0.8 1 4 3.9 0.3 3 4 
MMAS-8© Polypharmacy unintentional 3.5 0.6 2 4 3.7 0.4 2.8 4 
BP (systolic) 123.9 13 98 159 126.8 14.6 100 175 
BP(diastolic) 78.2 7.2 59 93 81 6.6 60 100 
Morisky score-8© = MMAS-8, Clinically useful depression outcomes scale = CUDOS, Clinically useful anxiety outcomes scale = CUXOS, SD(+/-) = 
standard deviation, BP = blood pressure. 
Data was then analyzed by all variables comparing group A 
to group B's measurable outcomes (Table 2). Group A 
showed a better adherence mean score for both diabetes 
medications and chronic diseases medications in both the 
physically active and inactive patients. The unemployed also 
showed a higher mean adherence score in the two groups. 
Other factors identified were; secondary school education, 
access to resources, not smoking, no diagnosis of MIH, and 
Bangladeshi heritage.  
CUDOS mean percentage was lower (better) in group A 
physically active (0.18%), group B unemployed (0.14%), 
group A patients with secondary school education, those with 
no access to resources, smokers, those who are treated for 
mental illness and patients from Bangladeshi heritage 
(0.17%, 0.18%, 0%, 0.17%, 0% respectively).  
There were no significant differences between groups and 
variants in the CUXOS mean scores, however, only patients 
from Pakistani heritage from group A remained above 1% till 
the end of the study.  
Wellbeing means the self-reported score was higher (better) 
in group B physically inactive (5), group A unemployed 
(4.75), group A patients with primary school education, those 
with no access to resources in group A (4.18), smokers in 
group A (4.67), those who are treated from mental illness 
from group B (4.5) and patients from Bangladeshi heritage in 
group B (4.67).
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Diabetes medications adherence 
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The medication adherence scores were split into intentional 
and unintentional, which distinguished participants’ behavior 
toward their diabetes medications adherence (Figures 2a and 
2b). There was no significant difference seen between the 
groups, however, a potentially important pattern of 
improvement was observed for group A whereas group B was 
seen to fall. This demonstrates the value of an additional, 
midterm encounter impacting patients’ intentional behavior 
toward their medication adherence.  
Chronic disease medications intentional adherence scores 
showed a greater improvement in group B participants when 
compared to group A. However, these results show that an 
extra encounter did not prove to be beneficial with the chronic 
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disease medication as both groups reached the same point of 
improvement (Figure 2c and 2d). 
Improvement in CUDOS© and CUXOS© scores was greater 
when patients were reviewed over a longer period (6-months) 
compared to those seen every 3-months (Figure 2e and 2f). 
Wellbeing scores were self-reported, there was no statistical 
difference between the groups however group A displayed 
better wellbeing scores when compared to group B. This 
showed the importance of having frequent encounters (3-
monthly) and the sense of being reassured by healthcare 
professionals (Figure 2g).  
The difference between baseline and endpoint for HbA1c 
shows no statistical difference, therefore, indicating no need 
for a further encounter (Figure 2h).  
For BP, both systolic and diastolic had raised in both groups 
but remained within range, with group A being slightly lower 
than group B. The results show a statistical difference 
between time points but no difference between the groups 
(Figure 2i and 2j).
  
a) Diabetes medication intentional adherence scores b) Diabetes medications unintentional adherence scores 
  
c) Chronic disease medication intentional adherence score 
d) Chronic disease medications unintentional adherence 
scores 
  
e) CUDOS© scores f) CUXOS© scores 
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g) Wellbeing score h) HbA1c results 
 
 
i) BP systolic readings j) BP diastolic readings 
Figure 2. Regression analysis by groups 
Thematic Analysis 
Using Braun et al. [16], the qualitative data were analyzed 
using a thematic approach. There were 12 identified themes. 
(Table 3). Those themes were used to develop the two 
proposed models for primary care (Figure 3). 
 







Awareness of condition prognosis. 31 51 
Awareness of how medications work. 15 58 
Awareness of the impact of lifestyle. 8 51 




Category 1: High self-care efficacy and favorable disease prognosis (disease markers are within 
the patient target range, good adherence to medications and lifestyle advice, no mental health 
issues). 
11 47 
Category 2: High self-care efficacy and poor disease prognosis (disease markers are out of the 
patient target range, good adherence to medications and lifestyle advice, no mental health issues). 
27 12 
Category 3: Poor self-care efficacy and favorable disease prognosis (disease markers are within 
the patient target range, low adherence to medications and lifestyle advice, mental health issues). 
4 0 
Category 4: Poor self-care efficacy and poor disease prognosis (disease markers are out of patient 
target range, low adherence to medications and lifestyle advice, mental health issues). 
23 5 
Future needs 
Ongoing monitoring required - patient at risk of non-adherence to therapy and lifestyle 28 5 
Ongoing monitoring required – patient at risk of mental health problems or illnesses 11 0 
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Ongoing monitoring required – patients require frequent health checks. 48 26 
Study impact Benefit from participating in the study (self-reported wellbeing score). 45 62 
Prediction Model  
Based on the thematic analysis, coupled with case 
characteristics and grouping, it was possible to identify four 
possible prediction phenomena. Patients who displayed this 
phenomenon shared some characteristics as illustrated in 
Table 4.
 
Table 4. Patients shared characteristics at baseline 
Phenomenon 
High self-care efficacy 
and favorable disease 
prognosis 
High self-care 
efficacy and poor 
disease prognosis 
Poor self-care efficacy 
and favorable disease 
prognosis 
Poor self-care 
efficacy and poor 
disease prognosis 
Age (years) 
















































Depression 0%-10% 11%-20% 0-10% 11-20% 














Number of conditions <3 4-5 4-5 <6 



























COVID-19 impact Yes Yes Yes Yes 
Phenomenon probability Possible Possible Impossible Possible 
The phenomena are confirmed as possible when shared by 
90% or more of the participants’ characteristics. Four 
possible models were identified and were used to develop the 
research recommendations.  
Impact on T2DM management in Bangladeshi and 
Pakistani patients 
Figure 3a displays a pictorial illustration for diabetes care for 
participants from the southeast Asian population of the 
Muslim faith. Based upon study findings, various adaptations 
are required t to manage T2DM at an optimum level of 
glycaemic control. Various religious, and personal views of 
participants were seen as restricting certain physical activities 
which need to be highlighted to the clinician to recognize and 
develop achievable goals as per the current guidelines NG28 
[17]. The study shows the importance of health education in 
the population group of Southeast Asians. Participants mainly 
had a background of primary or secondary education, which 
it was established the difference between the Pakistani and 
Bangladeshi heritage populations, and the difference in 
approach required to achieve optimal diabetes control. As 
seen in the algorithm, the power of a group session would 
enable a better understanding of dietary intake as well as 
physical activity sessions. This population showed 
individuals with a large number of children from multi-
occupant households. The idea of a group session can allow 
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household members to come and participate as a group and in 
essence, take the same message home together. It needs to be 
highlighted that these group sessions are founded on, and 
respectful of the participants’ cultural and religious 
background, therefore gender-specific groups, and when 
appropriate, age-specific groups will be required due to the 
religious beliefs of individuals. Both ethnic groups’ 
definitions, beliefs, and behaviors towards physical illness, 
mental illness, and wellbeing are derived from a combination 
of their own cultures and religion. Accordingly, physical 
activities, dietary plans, screening for adherence, and mental 
illness needs to be established in ways that work around those 
identified issues to make them practical and achievable.  
Impact of practice improvement for T2DM in 
primary care 
This study has shown how three monthly reviews do not 
allow the progression of an impact in glycaemic control or 
MIH but showed improvement in physical activity, diet, and 
wellbeing [18]. However, this was only observed for 6 
months which is not sufficient to accomplish behavior 
change. A four-monthly review by independent prescribers 
(from GP or community-based) is proposed to complement 
the usual care described in NICE guidelines including diet 
and physical health advice (Figure 3b).  
 
 
a) Prototype algorithm for patients diagnosed with T2DM tailored to Muslim Pakistani and Bangladeshi patients 
* Physical activity discussion: -Consider gardening, walking to work or shopping, -Consider activities that can be 
undertaken at the comfort of an individual’s house using alternative gym such as use of house furniture e.g., kitchen 
benches, food instead of weight etc 
**Diet discussion: -Consider that Pakistani and Bangladeshi patients differ culturally and consume different, -Food in 
different diary, fat and carbohydrate (complex and simple) proportions, -Consider portion control advise during cultural 
and religion events to compensate for type of consumed food to avoid upsetting culture trends 
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b) Prototype algorithm for patients diagnosed with T2DM 
Figure 3. Prototype algorithms 
Limitation 
This study had some limitations: Funding was the first hurdle. 
Numerous applications were rejected as it appeared a project 
led by a pharmacist was not considered by many funders as 
clinical research because it was led by an independent 
prescribing pharmacist, not a doctor or a nurse.  
Cultural sensitivity and norms also affected the study results, 
as all patients recruited were from Bangladeshi or Pakistani 
origin where essential aspects of the study remain 
stigmatizing and labeling if they are disclosed; aspects such 
as MIH, smoking, and alcohol consumption. Additionally, 
there were cultural appropriateness issues where participants 
feel societal obligations to participate in, or avoid, which are 
determinant for poor diabetes control such as food as the 
center of social gathering and celebrations, and gender 
restriction or obligations, such as the type of physical activity 
undertaken and large household responsibilities for females. 
This may have led to participants not being willing to disclose 
those aspects or respond to the questions, based upon their 
personal, cultural and religious beliefs. 
Site selection impact was also experienced. The area where 
the site is located in Birmingham is mostly populated by 
people of Southeast Asian origin.  
CONCLUSION 
The assessment of T2DM, depression, and anxiety was seen 
to be important to review in all encounters, however, the 
study has shown that a longer (6-months) interval between 
reviews was more beneficial than 3-months, whereas, with 
T2DM review, a significant difference was seen when the 
patient review was every 3-month compared to 6-months. 
The study demonstrated that current guidelines do not 
account for ethnicity and religion, or how these two factors 
can influence glycaemic control. This pilot study 
demonstrated clear potential for the use of MMAS-8© 
Widget and CUDOS©/CUXOS© screening. The structure 
within the NHS in recent years has dramatically changed 
allowing more pharmacists to be employed in primary care. 
The tools can be used as part of the structured medication 
reviews (SMR) to enable the detection of adherence issues.  
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